Blog
RSS FeedPosted by Michael Wonder on 28 Jan 2022
'I feel like I'm drowning': thousands with cystic fibrosis wait to hear if 'life-saving' drug will be listed on PBS
27 January 2022 - Matt Dickinson was struggling to breathe when his mother rushed him to an Adelaide hospital earlier ...
Posted by Michael Wonder on 28 Jan 2022
Australians deserve fast access to the latest medicines, vaccines and treatments
28 January 2022 - Medicines Australia recommends the Australian Government delivers a plan to shorten the time that patients wait ...
Posted by Michael Wonder on 27 Jan 2022
Positive Early Access to Medicines Scheme (EAMS) scientific opinion awarded to GBT’s voxelotor for the treatment of haemolytic anaemia due to sickle cell disease
27 January 2022 - Global Blood Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded ...
Posted by Michael Wonder on 26 Jan 2022
Former bowel cancer patient calls for NZ to fund drug she says saved her life
26 January 2022 - A woman with bowel cancer who was told she may have two years to live says ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...
Posted by Michael Wonder on 24 Jan 2022
Breast cancer patients in Scotland are set to receive tumour blasting wonder drug that starts working in weeks - sparking hopes of a wider rollout for NHS patients across the rest of the UK
23 January 2022 - A breast cancer drug that can melt away tumours in weeks has been given the green ...
Posted by Michael Wonder on 24 Jan 2022
People with chronic myeloid leukaemia granted early access to Novartis’ investigational treatment
24 January 2022 - The Medicine and Healthcare products Regulatory Agency grants positive scientific opinion on use of asciminib as 3rd-line ...
Posted by Michael Wonder on 24 Jan 2022
Novavax COVID-19 vaccine to be available in coming weeks
24 January 2022 - Australians aged 18+ will now have access to a fourth COVID-19 vaccine, Nuvaxovid (Novavax) in coming weeks, ...
Posted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 24 Jan 2022
Australians with severe dermatitis to benefit from PBS listing
24 January 2022 - From 1 February 2022, Australians with severe atopic dermatitis will have access to a new treatment ...
Posted by Michael Wonder on 23 Jan 2022
Thousands to benefit from decision to subsidise eczema treatment
23 January 2022 - Australians suffering from a severe form of eczema will save tens of thousands of dollars after a ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 22 Jan 2022
Patent thickets are thwarting U.S. availability of lower cost biosimilar medicines, study finds
18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...
Posted by Michael Wonder on 17 Jan 2022
Keytruda reimbursement boosts MSD’s R&D of follow-up drug
17 January 2022 - The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer ...
Posted by Michael Wonder on 17 Jan 2022
$421,000 cancer drug Kymriah becomes eligible for reimbursement
14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become ...